Insider buying last 90 days
No open-market insider purchases were filed for INSM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
This week's news centers on Insmed's third-quarter update, in which the company raised full-year 2026 guidance for BRINSUPRI and ARIKAYCE after exceeding $1 billion in total company revenue year-to-date, with BRINSUPRI surpassing $1 billion in revenue across its first four full quarters. Analyst activity followed, with H.C. Wainwright initiating coverage with a buy rating and a $220.00 price target, citing peak sales guidance exceeding $14 billion across the respiratory portfolio, while another commentary set fair value near $99 against a $110 share price. Management also announced presentations at the Jefferies Global Healthcare Conference on 16 November and the Evercore 9th Annual Healthcare Conference on 1 December.
Shares closed at $116.10, up 1.5%, sitting between the 50-day moving average of $111.16 and the 200-day average of $123.95. The GekkoIndex reads 52.2, placing the stock in the Neutral zone, with the five-day change at -0.9. Price sits 19% below Gekko Fair Value of $143.31.
The next earnings date falls on 18 February 2027, 100 days out and beyond a typical 20-trading-day holding window. Over the last 30 days, one unusual options signal appeared, with call premium of $3,334,530 against no put premium. Seasonality over 5 years shows the next 20 trading days averaging a 1.8% return, higher in 4 of those years. Consensus among 17 firms stands at 16 buy and 1 hold, with a consensus target of $194.18.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Insmed scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $121.16 sits between the 50-day ($110.82) and 200-day ($123.16) averages, or the averages disagree.
See the chart50.9, Neutral
Reading 50.9 is in the Neutral zone.
See the GekkoIndex15.6% below
Price is 15.6% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 95 days
Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.
See earnings+2.9% on average
From this point in the calendar, the next 20 trading days averaged +2.9% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Insmed closed at $121.16 on Nov 13, 2026, −37.7% over the past year, inside a 52-week range of $90.39 to $212.75.
Use the left and right arrow keys to read daily values.
Put INSM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Insmed is a biopharmaceutical company that develops treatments for people with serious and rare diseases. Its approved product, ARIKAYCE, is used by adult patients with Mycobacterium avium complex lung disease, given as part of a wider antibacterial treatment plan. The company is best known for this therapy alongside a pipeline of experimental treatments aimed at difficult-to-treat conditions.
Beyond its marketed product, Insmed is working on Brensocatib, an oral compound that inhibits an enzyme called dipeptidyl peptidase 1, being studied for bronchiectasis and other conditions driven by neutrophils. It is also developing an inhaled form of a treprostinil palmitil prodrug, intended for pulmonary arterial hypertension and other rare lung diseases. Its work centers on patients whose conditions are uncommon and often underserved by existing treatment options.
Insmed was founded in 1988 and is headquartered in Bridgewater, New Jersey. Its shares are listed on the NASDAQ under the ticker INSM.
Insmed’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.9, in the Neutral zone, down 2.4 points over five sessions.
Down 2.4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 22 | +9.3% | +14.8% |
| Accumulation | 259 | +2.3% | +7.7% |
| Neutral (current zone) | 360 | +0.3% | +4.0% |
| Distribution | 51 | +2.4% | +10.7% |
| Selling | 10 | +3.2% | +8.0% |
Average INSM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Insmed trades 15.6% below Gekko Fair Value of $143.59, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Insmed shares are worth, recalculated every trading day.
$143.59
Gekko Fair Value, Nov 14, 2026
15.6% Undervalued
At the end of Aug 2026 the price was 28.3% below the estimate.
No open-market insider purchases were filed for Insmed, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for INSM in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in INSM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Oct 23, $3.33M in unusual premium.
1of the funds Gekko tracks holds INSM.
Insmed reports on Feb 18, 2027, before the open (95 days away), and beat the EPS estimate in 2 of its last 8 reports.
Feb 18, 2027
Expected before the open, 95 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | −$0.46 est −$0.38 | $524.4M est $500.4M | +16.1% |
| Aug 6, 2026 | −$0.52 est −$0.69 | $425.5M est $395.5M | +32.4% |
| May 7, 2026 | −$0.76 est −$1.00 | $306.0M est $300.8M | −26.1% |
| Feb 19, 2026 | −$1.54 est −$1.07 | $263.8M est $231.2M | +9.1% |
| Oct 30, 2025 | −$1.75 est −$1.37 | $142.3M est $115.4M | +13.6% |
| Aug 7, 2025 | −$1.70 est −$1.30 | $107.4M est $104.1M | −1.5% |
| May 8, 2025 | −$1.42 est −$1.20 | $92.82M est $91.47M | −4.7% |
| Feb 20, 2025 | −$1.32 est −$1.23 | $104.4M est $102.1M | −3.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Insmed is $194.18, +60.3% from the last close, from 17 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 17 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 5 | Evercore ISI | $170 | +40.3% |
| Nov 4 | H.C. Wainwright | $220 | +81.6% |
| Nov 3 | Mizuho Securities | $158 | +30.4% |
| Nov 2 | BMO Capital | $192 | +58.5% |
| Nov 2 | Barclays | $207 | +70.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Insmed averaged +2.9% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.2% | 2 of 5 |
| Next 10 trading days | +1.0% | 3 of 5 |
| Next 15 trading days | +2.3% | 4 of 5 |
| Next 20 trading days | +2.9% | 4 of 5 |
| Next 30 trading days | +1.4% | 1 of 5 |
For scale, INSM’s typical 20-trading-day move in either direction is about 8.1%.
Insmed’s market cap is $26.58B and revenue of $1.52B over the last twelve months.
Coverage of Insmed this week reads positive: 2 positive, 1 neutral and 1 negative headlines.
Insmed’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Insmed’s market cap is $26.58B at the Nov 13, 2026 close of $121.16, with 219.4M shares outstanding.
The consensus analyst 12-month price target for Insmed is $194.18, +60.3% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Insmed is undervalued: the Nov 13, 2026 close of $121.16 is 15.6% below Gekko Fair Value of $143.59. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Insmed is expected to report on Feb 18, 2027, before the market opens (95 days away). Analysts expect earnings of −$0.31 per share on revenue of $601.7M. Insmed beat the earnings estimate in 2 of its last 8 reports, moving 13.3% on average across the report.
Insmed’s 52-week high is $212.75 and its 52-week low is $90.39; it closed at $121.16 on Nov 13, 2026, −37.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (fair value, smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Insmed over the last 30 days, with $3.33M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Oct 23, 2026 with $3.33M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.